Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019032945) CD40-BINDING AGENTS AND USES THEREOF
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/032945 International Application No.: PCT/US2018/046186
Publication Date: 14.02.2019 International Filing Date: 10.08.2018
IPC:
A61K 38/19 (2006.01) ,A61K 39/395 (2006.01) ,C07K 16/18 (2006.01) ,C07K 16/24 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
ONCOMED PHARMACEUTICALS, INC. [US/US]; 800 Chesapeake Drive Redwood City, California 94063, US
Inventors:
GURNEY, Austin L.; US
SRIVASTAVA, Minu K.; US
Agent:
CALVO, Paul A.; US
BANOWIT, Donald R.; US
BEZOS, Salvador M.; US
BODENSTEIN, Matthew; US
CAMARCE, Christian; US
CIMBALA, Michelle A.; US
COLLER III, Richard D.; US
CONKLIN, Kyle; US
CORNWELL, David K.S.; US
COVERT, John M.; US
DESAI, Nirav N.; US
DURKIN, Tracy-Gene G.; US
EISENBERG, Jason D.; US
ELLISON, Eldora L.; US
ESMOND, Robert W.; US
FEATHERSTONE, Donald J.; US
FRUEAUF, Jeremiah B.; US
GAJEWSKI, Daniel; US
GILLENTINE, Marsha Rose; US
GOLDSTEIN, Jorge A.; US
GORDON, Lori A.; US
HELVEY, Jeffrey T.; US
HICKS, Ross G.; US
HOLOUBEK, Michelle K.; US
JACKMAN, Peter A.; US
KIM, Ji-Eun; US
LAROCK, Adam; US
LEE, Michael Q.; US
LONGSWORTH, Gaby L.; US
MILLONIG, Robert C.; US
MUTSCHELKNAUS, Joseph E.; US
NANNENGA-COMBS, Bonnie; US
PICKARD, Byron L.; US
POWERS, Trey; US
RAY, Michael B.; US
RYGIEL, Mark W.; US
SHEA, JR, Timothy J.; US
SOKOHL, Robert E.; US
SPECHT, Michael D.; US
STEFFE, Eric K.; US
STERLING, Deborah A.; US
STERNE, Robert Greene; US
STRANG, Jonathan M.; US
TUMINARO, Jonathan; US
VARUGHESE, Dennies; US
VIRA, Chandrika; US
WRIGHT, Jon E.; US
YONAN, Daniel E.; US
Priority Data:
62/543,73410.08.2017US
Title (EN) CD40-BINDING AGENTS AND USES THEREOF
(FR) AGENT LIANT CD40 ET UTILISATIONS ASSOCIÉES
Abstract:
(EN) Polypeptides and agents that bind human CD40 are disclosed. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising the extracellular domain of CD40L or a fragment thereof, wherein the extracellular domain of CD40L or fragment thereof comprises a mutation in the integrin-binding region. The agents may include bispecific and multispecific agents. Also disclosed are methods of using the polypeptides or agents for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.
(FR) L'invention concerne des polypeptides et des agents qui se lient au CD40 humain. Les polypeptides ou les agents peuvent comprendre des polypeptides de fusion, en particulier des polypeptides comprenant le domaine extracellulaire de CD40L ou un fragment de celui-ci, le domaine extracellulaire de CD40L ou un fragment de celui-ci comprenant une mutation dans la région de liaison à l'intégrine. Les agents peuvent comprendre des agents bispécifiques et multispécifiques. L'invention concerne également des procédés d'utilisation de ces polypeptides ou agents pour induire et/ou améliorer la réponse immunitaire, ainsi que des procédés de traitement de maladies telles que le cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)